Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development.

× No keyword cloud information.

4 in total

1. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Authors: Kayleigh J Mason; Jonathan N W N Barker; Catherine H Smith; Philip J Hampton; Mark Lunt; Kathleen McElhone; Richard B Warren; Zenas Z N Yiu; Christopher E M Griffiths; A David Burden
Journal: JAMA Dermatol Date: 2018-05-01 Impact factor: 10.282

2. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).

Authors: R Bissonnette; T Luger; D Thaçi; D Toth; A Lacombe; S Xia; R Mazur; M Patekar; P Charef; M Milutinovic; C Leonardi; U Mrowietz
Journal: J Eur Acad Dermatol Venereol Date: 2018-03-22 Impact factor: 6.166

3. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.

Authors: Z Z N Yiu; K J Mason; J N W N Barker; P J Hampton; K McElhone; C H Smith; R B Warren; C E M Griffiths; M Lunt; A D Burden
Journal: Br J Dermatol Date: 2019-07-02 Impact factor: 9.302

4. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.

Authors: A Blauvelt; C Paul; P van de Kerkhof; R B Warren; A B Gottlieb; R G Langley; F Brock; C Arendt; M Boehnlein; M Lebwohl; K Reich
Journal: Br J Dermatol Date: 2020-09-06 Impact factor: 9.302

4 in total